http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Image Coding and Processing in Personal Computer
Cheung, R. W. L.,Liu, P. C. K.,Leung, C. K. 대한전자공학회 1994 ISPACS:Intelligent Signal Processing and Communica Vol.1 No.1
A simple technique based on PC image coding is developed to simulate a printer output of a picture on the monitor screen in a PC. During the process of .simulation of the printed image produced by the selected matrix printer, the image ,processing techniques are applied Most ,importantly, a palette consists of 20 pre-defined gray levels is read through by a scanner and the resulted file is seat to the PC for subsequent processing and analysis.
The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers
Han, L.,Diao, L.,Yu, S.,Xu, X.,Li, J.,Zhang, R.,Yang, Y.,Werner, Henrica M.J.,Eterovic, A.,Yuan, Y.,Li, J.,Nair, N.,Minelli, R.,Tsang, Y.,Cheung, Lydia W.T.,Jeong, K.,Roszik, J.,Ju, Z.,Woodman, Scott Cell Press 2015 CANCER CELL Vol. No.
Adenosine-to-inosine (A-to-I) RNA editing is a widespread post-transcriptional mechanism, but its genomic landscape and clinical relevance in cancer have not been investigated systematically. We characterized the global A-to-I RNA editing profiles of 6,236 patient samples of 17 cancer types from The Cancer Genome Atlas and revealed a striking diversity of altered RNA-editing patterns in tumors relative to normal tissues. We identified an appreciable number of clinically relevant editing events, many of which are in noncoding regions. We experimentally demonstrated the effects of several cross-tumor nonsynonymous RNA editing events on cell viability and provide the evidence that RNA editing could selectively affect drug sensitivity. These results highlight RNA editing as an exciting theme for investigating cancer mechanisms, biomarkers, and treatments.
Knox, J. J.,Barrios, C. H.,Kim, T. M.,Cosgriff, T.,Srimuninnimit, V.,Pittman, K.,Sabbatini, R.,Rha, S. Y.,Flaig, T. W.,Page, R. D.,Beck, J. T.,Cheung, F.,Yadav, S.,Patel, P.,Geoffrois, L.,Niolat, J.,B Oxford University Press 2017 ANNALS OF ONCOLOGY Vol.28 No.6
<P><B>Background</B></P><P>RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluated mature data for secondary end points.</P><P><B>Patients and methods</B></P><P>Patients received either first-line everolimus followed by second-line sunitinib at progression (<I>n = </I>238) or first-line sunitinib followed by second-line everolimus (<I>n = </I>233). Secondary end points were combined first- and second-line progression-free survival (PFS), OS, and safety. The impacts of neutrophil lymphocyte ratio (NLR) and baseline levels of soluble biomarkers on OS were explored.</P><P><B>Results</B></P><P>At final analysis, median duration of exposure was 5.6 months for everolimus and 8.3 months for sunitinib. Median combined PFS was 21.7 months [95% confidence interval (CI) 15.1–26.7] with everolimus-sunitinib and 22.2 months (95% CI 16.0–29.8) with sunitinib-everolimus [hazard ratio (HR)<SUB>EVE-SUN/SUN-EVE</SUB>, 1.2; 95% CI 0.9–1.6]. Median OS was 22.4 months (95% CI 18.6–33.3) for everolimus-sunitinib and 29.5 months (95% CI 22.8–33.1) for sunitinib-everolimus (HR<SUB>EVE-SUN/SUN-EVE</SUB>, 1.1; 95% CI 0.9–1.4). The rates of grade 3 and 4 adverse events suspected to be related to second-line therapy were 47% with everolimus and 57% with sunitinib. Higher NLR and 12 soluble biomarker levels were identified as prognostic markers for poor OS with the association being largely independent of treatment sequences.</P><P><B>Conclusions</B></P><P>Results of this final OS analysis support the sequence of sunitinib followed by everolimus at progression in patients with mRCC. The safety profiles of everolimus and sunitinib were consistent with those previously reported, and there were no unexpected safety signals.</P><P><B>Clinical Trials number</B></P><P>ClinicalTrials.gov identifier, NCT00903175</P>